These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22537810)

  • 1. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.
    Williams KL; Wahala WM; Orozco S; de Silva AM; Harris E
    Virology; 2012 Jul; 429(1):12-20. PubMed ID: 22537810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
    Wahala WM; Huang C; Butrapet S; White LJ; de Silva AM
    J Virol; 2012 Apr; 86(7):4019-23. PubMed ID: 22278250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.
    Nilchan N; Kraivong R; Luangaram P; Phungsom A; Tantiwatcharakunthon M; Traewachiwiphak S; Prommool T; Punyadee N; Avirutnan P; Duangchinda T; Malasit P; Puttikhunt C
    ACS Infect Dis; 2024 Aug; 10(8):2690-2704. PubMed ID: 38943594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
    Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
    Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
    Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
    Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
    Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
    Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
    Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.
    Ali S; Afzal S; Yousaf MZ; Shahid M; Amin I; Idrees M; Aftab A
    Crit Rev Eukaryot Gene Expr; 2020; 30(3):199-206. PubMed ID: 32749106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional properties of DENV EDIII‑reactive antibodies in human DENV‑1‑infected sera and rabbit antiserum to EDIII.
    Chen J; Wen K; Li XQ; Yi HS; Ding XX; Huang YF; Pan YX; Hu DM; Di B; Che XY; Fu N
    Mol Med Rep; 2016 Aug; 14(2):1799-808. PubMed ID: 27357403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
    J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model.
    Zhou Y; Chen D; Yang L; Zou W; Duan Z; Zhang Y; Wen J
    Virus Res; 2020 Mar; 278():197882. PubMed ID: 31981774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli.
    Yang J; Zhang J; Chen W; Hu Z; Zhu J; Fang X; Yuan W; Li M; Hu X; Tan Y; Hu F; Rao X
    Can J Microbiol; 2012 Apr; 58(4):369-80. PubMed ID: 22420529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
    Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
    Front Immunol; 2019; 10():59. PubMed ID: 30761131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.